Matthew Rice, a project manager in the Therapeutics Development Branch within NCATS’ Division of Preclinical Innovation, supports the Center’s role in the Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM. In that position, he manages early therapeutic development projects in the NIH HEAL Initiative portfolio.
Prior to joining NCATS, Rice developed and conducted a wide range of neuroscience-related research projects, including the use of nanoparticles as hemostatic agents for intracerebral hemorrhage; the acute application of nicotine to treat brain injury–induced motor and cognitive deficits; the utility of targeting the microbiota-gut-brain axis for the treatment of brain injury pathology and symptomatology; the efficacy of human neural stem cells for severe penetrating traumatic brain injury; the evaluation of countermeasures to chemical nerve agents; the contribution of hypothalamic neuroendocrine signaling in aging; the application of neural stem cells in the treatment of metabolic syndrome pathologies; and the role of the dopaminergic system in schizophrenia.
Rice received his bachelor’s degree in psychology from East Tennessee State University and his doctorate in behavioral neuroscience from The University of Alabama at Birmingham. He completed his postdoctoral training at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Chemical Defense.
Rice’s research interests are in behavioral neuroscience and in vivo pharmacology as it relates to the early development of therapeutics to combat long-term addiction.